Brainmarker Suite

Better mental healthcare starts with better information.

Accurate diagnosis is the foundation of effective treatment. The Brainmarker Suite provides clinicians with objective, scientifically validated insights that support more informed diagnostic and treatment decisions.

Developed by The Brainclinics Foundation in close collaboration with Synaeda, the Brainmarker Suite combines EEG analysis, validated questionnaires, cognitive assessments, and physiological measurements into a single integrated diagnostic platform. Using advanced algorithms and automated analysis, complex neurophysiological data are transformed into clear, clinically actionable insights that are available within minutes.

Psychiatry has traditionally relied on clinical interviews, observations, and questionnaires. While these remain essential, they do not always provide the complete picture.

The Brainmarker Suite adds an objective biological dimension by combining EEG-based brain biomarkers with patient-reported outcome measures (PROMs), cognitive performance, and physiological assessments. This provides a more comprehensive view of a patient’s functioning and gives clinicians additional evidence to support diagnostic assessment and treatment planning.

All data are processed through a single integrated workflow. Results are presented in an interactive dashboard featuring objective outcome measures, clinically relevant brain biomarkers, and clear visualizations that are easy to interpret.

The Brainmarker Suite is built on more than twenty years of international research in EEG, neuroscience, and brain biomarkers, led by The Brainclinics Foundation, with significant contributions from researchers at Synaeda.

The platform was developed according to the principle of ‘from the clinic, to the clinic’: translating scientific discoveries into practical applications that directly contribute to better mental healthcare.

Research has identified several EEG-based brain biomarkers, including Brainmarker-I, that can support treatment planning for specific patient populations. Thanks to a fully automated analysis pipeline, these validated research findings have been translated into tools that are readily accessible for everyday clinical practice.

Interpreting EEG data has traditionally required specialized expertise and considerable time. The Brainmarker Suite automates this process, presenting the results in a clear and intuitive reporting dashboard.

Questionnaire results, EEG biomarkers, and heart–brain measurements are presented in an integrated view, enabling complex data to be interpreted quickly and consistently. This streamlined workflow reduces processing time from hours -or even days- to just a few minutes, without compromising scientific quality, reliability, or reproducibility.

That means more time and personal attention for the patient.

We believe the future of mental healthcare lies in combining clinical expertise with objective brain biomarkers and intelligent data analysis.

Technology does not replace the clinician -it supports clinical decision-making by providing objective information on which better-informed decisions can be based. After all, high-quality care begins and ends with the relationship between clinician and patient.

The Brainmarker Suite is a continuously evolving platform. New biomarkers, advanced analytical methods, and ongoing developments in intelligent data analysis will continue to deliver increasingly precise clinical insights in the years ahead. Step by step, we are helping make precision psychiatry accessible to more and more patients.

The Brainmarker Suite is used in clinical practice, scientific research, and international collaborations. The platform is available in multiple languages and can be tailored to the needs of different healthcare organizations and research institutions.

Synaeda is responsible for the ongoing development, implementation, and support of the Brainmarker Suite. Healthcare organizations, research institutes, and commercial partners can license the platform through Synaeda. We provide implementation support, training, and continuous development, enabling organizations to fully benefit from objective biomarkers and innovative neurodiagnostics.

From science to care.

From data to insight.

From insight to better treatment.